Viventia Bio Overview
- Founded
-
1995
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
4
Viventia Bio General Information
Description
Producer of biopharmaceuticals. The company is engaged in the identification, development, production and marketing of biopharmaceuticals specializing in human monoclonal antibody therapies for the treatment of cancer.
Contact Information
Website
www.viventia.com
Formerly Known As
Novopharm Biotech
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- 147 Hamelin Street
- Winnipeg, Manitoba R3T 3Z1
- Canada
Viventia Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Viventia Bio Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Producer of biopharmaceuticals. The company is engaged in the identification, development, production and marketing of b
Biotechnology
Winnipeg, Canada
00.00
0000-00-00
000000&0
000000
sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis no
0000000000000
San Diego, CA
00
As of 0000
000.00
0000
0000-00-00
000000&0
000.00
00000
si ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit ess
0000 000000000
Cambridge, United Kingdom
000
As of 0000
00000
0.000
0000-00-00
000000&0
00000
Add Comparison
Viventia Bio Competitors (76)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfenex | Formerly VC-backed | San Diego, CA | 00 | 000.00 | 000000&0 | 000.00 |
| 00000 | Formerly VC-backed | Cambridge, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
| 00000000 | Corporation | Austin, TX | 00 | 0000 | 00000000 | 0000 |
| 00000000 00000000 | Corporate Backed or Acquired | College Station, TX | 000 | 0000000000 | ||
| 000000 00000000000 | Formerly PE-Backed | South San Francisco, CA | 00 | 00000 | 000000&0 | 00000 |
Viventia Bio Patents
Viventia Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-6847846-B2 | Dosing strategies targeting epcam-positive bladder cancer | Active | 12-Mar-2015 | 000000000 | |
| US-10583198-B2 | Dosing strategies for targeting epcam positive bladder cancer | Active | 12-Mar-2015 | 000000000 | 00 |
| US-20180104355-A1 | Dosing strategies for targeting epcam positive bladder cancer | Granted | 12-Mar-2015 | 00000000000 | |
| JP-2018512402-A | Dosing strategy targeting epcam positive bladder cancer | Granted | 12-Mar-2015 | 00000000000 | 0 |
| CA-2979400-A1 | Dosing strategies for targeting epcam positive bladder cancer | Pending | 12-Mar-2015 | A61K47/6861 |
Viventia Bio Executive Team (5)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Gregory Adams Ph.D | Chief Development Officer | ||
| Stephen Hurly | Director, President & Chief Executive Officer |
Viventia Bio Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000000 000000 00.0 | Self | Board Member | 000 0000 |
Viventia Bio Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|